We previously reported the efficacy of anti-cancer therapy with hyperthermia using an alternating magnetic field (AMF) and a magnetic compound. In the course of the study, unexpectedly, we found that an AMF enhances the cytotoxicity of Compound C, an activated protein kinase (AMPK) inhibitor, although this compound is not magnetic. Therefore, we examined the cellular mechanism of AMF-induced 
as a sensor of the intracellular energy charge, which is activated by increasing AMP coupled with decreasing ATP. 4 AMPK is activated under environmental conditions in various cells and plays a critical role in systemic energy balance. Rois et al demonstrate that AMPK activation is essential for the proliferation of astrocytic tumor cells by promoting cell-cycle progression in both mice and humans. 5 Compound C (6-[4-(2-Piperidin-1-ylethoxy) phenyl]-3-pyridin-4-ylpyrazolo [1,5-a] pyrimidine) is a cell permeable AMPK inhibitor, which is the only available agent. Compound C (BML-275) induced apoptosis in myeloma, glioma, breast carcinoma and prostate cancer cells. [6] [7] [8] [9] Compound C also induced the accumulation of G2-M in the cell cycle in glioma. 8 Lui et al report that Compound C is an extremely potent anti-glioma agent; however, it has little effect on the human astrocyte. 10 Recently, intratumoral hyperthermic therapy for GB using magnetic iron-oxide nanoparticles (Fe 3 O 4 ) directly injected into the tumor and exposed to an alternating magnetic field (AMF) to generate heat has been investigated. 11, 12 Furthermore, Optune (formerly known as NovoTTF-100A, Novocure, Jersey, Israel) was approved for use with TMZ for the treatment of adults with newly diagnosed supratentorial glioblastoma multiforme (GBM) after maximal surgical reduction and completion of radiation. 13 The common feature of these novel treatments is the application of a physical phenomenon.
We have previously examined hyperthermia treatment for tumors using magnetic material and an AMF. [14] [15] [16] [17] In the course of our study, we unexpectedly found that an AMF increased the cytotoxicity of an AMP-activated protein kinase (AMPK) inhibitor, that is, Compound C, which is not a magnetic material. Several reports have explored the application of an AMF. In 1994, whole body pulsed magnetic field (PMF) exposure for 1 hour suppressed tumor growth when combined with cisplatin, carboplatin or doxorubicin treatment in vivo. 18 Similarly, a PMF (1.5 mT peak, repeated at 1 and 25 Hz) increased the cytotoxicity of vincristine (VCR), mitomycin C (MMC) and cisplatin. 19 However, the mechanism remains elusive. Our condition of the AMF (280 kHz, 250 Arms) is much different from the previous reports, especially the frequency.
This is the first report of an AMF being applied in the treatment of GB in combination with the anti-tumor agent, Compound C. We propose that the application of an AMF for cancer therapy may be a simple and promising method, which might reduce the dose and, thus, the side effects of chemotherapy in future cancer treatments. 
| MATERIALS AND METHODS

| Reagents and cell culture
| Thermometer and thermography
A thermometer (fibre optic thermometer FL-2400, Anritsu Meter
Co., Tokyo, Japan) or a thermograph (InfraRed camera, Nippon Avionics Co., Ltd., Tokyo, Japan) was used to determine the temperature in vitro. 21 
| XTT assay
A cell proliferation assay was performed using a commercial kit, the XTT Cell Proliferation Assay Kit (Biological Industries, Beit Haemek, Israel), as previously described. 21, 22 U251, T98, A172, MCF7, PANC1
and NHA cells were seeded on 96-well plates at 5.0 × 10 3 cells (Figure 1F , Figure 2B , Figure 4D and Figure 6A ) or 1.0 × 10 4 cells (Figure 1E , Figure 2A and Figure 5D ) per well. The cells were incubated for 24 hours in an atmosphere of 5% CO 2 in air at 37°C in the presence of Compound C, with or without 30 minutes of exposure to an AMF.
| In vivo imaging system analysis
The in vivo imaging system (IVIS) analysis was performed as reported. 21, 23 U251 cells expressing the luciferase gene were seeded on a 4-cm dish (1.5 × 10 5 cells per dish) and incubated for 1 day. 21 Then, 5 μmol/L Compound C was added, and the cells were stimulated with or without AMF for 30 minutes. At 24 hours after combined therapy with Compound C and an AMF, D-luciferin (4.7 mg/well) was added. After 15 minutes, the bioluminescence signal (proportional to the number of surviving cells) was examined using an IVIS.
| The measurement of reactive oxygen species
The measurement of reactive oxygen species (ROS) was performed as previously reported. 15, 24 The GB cells were incubated overnight in 96-well plates (2.0 × 10 4 cells per well) and then exposed to Compound C with or without 30 minutes of AMF exposure at 37°C for 24 hours.
| Apoptosis assay
Apoptosis assays were performed as previously described. 
| Cell cycle analysis
Cell cycle analysis was performed using the Cycletest TM Plus DNA Reagent Kit (BD Biosciences) according to the manufacturer's protocol. 23 
| Western blotting
Western blot analyses were performed as previously described. 25, 26 Briefly, the cells were lysed and sonicated in RIPA buffer (Thermo Scientific, Rockford, IL, USA). Equal amounts of protein were subjected to SDS-PAGE. After electrophoretic separation, the protein bands were transferred to a Millipore Immobilon-P membrane followed by immunoblotting with antibodies against molecules of interest. The following primary antibodies were used for immunoblotting: Bcl2, BAX, cleaved caspase-3, phospho-ERK, Akt, phospho-Akt, mTOR, phosphomTOR, raptor, phospho-raptor, p70S6K, phospho-p70S6K, 4EBP1, phospho-4EBP1,GAPDH and LC3B, obtained from CST (Cell Signaling Technology, Beverly, MA, USA), as well as ERK, obtained from SCBT (Santa Cruz Biotechnology, Dallas, TX, USA). Detection was performed using anti-rabbit or anti-mouse secondary antibodies followed by Clarity Western ECL Substrate (Bio-Rad, Hercules, CA, USA).
| Detection of autophagic flux
The formation of autophagosomes and autophagolysomes was detected in T98 cells using the Premo Autophagy Tandem Sensor RFP-GFP-LC3B Kit (Thermo Fischer Scientific, Grand Island, NY, USA). 27 The cells were grown on coverslips and incubated with component A containing the RFPGFP-LC3B overnight. The cells were then treated with vehicle or 5 μmol/L Compound C for 24 hours with/without AMF for 30 minutes.
| Data analysis and statistics
Values represent the means ± SEM. Statistical comparisons among groups were performed using Student's t-test or 1-factor ANOVA A, Applications of the AMF for longer than 30 min increased the Compound C-induced cytotoxicity in T98, U251, and A172 cells (n = 4; ns, not significant; *P < 0.05, ***P < 0.001). B, Compound C at 1 or 5 μmol/L exhibited cytotoxicity when combined with the AMF for 30 min in T98, U251 and A172 cells (n = 4; ns, not significant; *P < 0.05,**P < 0.01, ***P < 0.001). C, Viability analysis in the presence/absence of Compound C with/without the AMF for 30 min in U251 cells, which have been engineered to express the firefly luciferase gene. The viability of U251 cells was measured in terms of photon flux measured with an in vivo imaging system (IVIS). D, Quantification of cell viability with an IVIS imaging system. D, Effect of AMF for 30 min on ROS production in the absence/presence of Compound C (5 μmol/L) and the cell number counts for T98, U251 and A172 cells using the trypan blue assay (n = 4; ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001) with the Bonferroni post-hoc test. A P value of less than 0.05 was considered statistically significant.
| RESULTS
| Compound C suppressed cell growth in glioblastoma cells and normal human astrocytes
We previously reported that hyperthermia generated with ferucarbotran (Risovist) in an AMF enhanced cisplatin-induced apoptosis of oral cancer cells in culture. 16 Similarly, we demonstrated that the use of hyperthermia and chemotherapy with μ-oxo N,N′-bis(salicylidene)ethylenediamine iron [Fe(Salen)], a magnetic organic compound, greatly enhanced its cytotoxicity in oral cancer and glioblastoma because Fe(Salen) generates heat when exposed to an AMF and exhibited a hyperthermic effect. 15, 17 In the course of our study, we hypothesized that an AMF enhanced the cytotoxicity of an anti-tumor agent that does not possess magnetism.
To examine the effect of an AMF in the presence of Compound C, we used a commercial AMF generator equipped with a solenoid coil in the same condition (280 kHz, 250 Arms) as previously reported ( Figure 1A ). [15] [16] [17] The sample dish was placed above the center of the coil ( Figure 1B) . To exclude the effect of heat generation from the coil, we checked its temperature using thermography. The results showed that the temperature of the solenoid coil rose to less than 36°C for 90 minutes ( Figure 1C,D) .
Similarly, the temperature of the coil according to a thermometer We first examined the cytotoxicity of Compound C. As mentioned above, Compound C is a cell-permeable AMPK inhibitor.
Compound C exhibited cytotoxicity in gliomas. 10 In the current study, Compound C suppressed the cell proliferation of GB cells (T98 and U251) and normal human astrocytes (NHA) in a dosedependent manner ( Figure 1E ). However, Compound C exhibited cytotoxicity in NHA, and its effect in normal human astrocytes was less than that in glioma cells, indicating that the difference in efficacy between cancer cells and normal cells may contribute to a reduction in its side effects.
We next examined whether an AMF exhibited cytotoxicity in normal cells, namely, NHA. We found that the AMF did not exhibit cytotoxicity in NHA in this condition. (Figure 1F ). were engineered to express the firefly luciferase gene ( Figure 2C ).
These results are in accord with the result in Figure 2A .
It is reported that Compound C-induced ROS generation in skin cancer and pancreatic cancer cells. 28, 29 Therefore, we next evaluated whether the AMF promotes Compound C-induced ROS production.
We found that Compound C increased ROS production, and the AMF further promoted Compound C-induced ROS production in T98, U251 and A172 cell lines ( Figure 2D ). In contrast, AMF did not change ROS generation in normal cells (NHA) ( Figure S2 ). These data suggested that an AMF in the presence of Compound C enhanced cytotoxicity by increasing ROS production in GB cell lines. 
| An alternating magnetic field decreased Compound C-induced ERK phosphorylation and increased BAX/Bcl2 and caspase-3 expression in the presence of Compound C
AMPK is a key regulator of cellular energy metabolism and is activated under metabolic stress for survival. 10 To examine the effect of AKIMOTO ET AL. an AMF, we next investigated a mechanism whereby an AMF enhanced the cytotoxicity of Compound C in GB cells. Compound C blocked the Akt/mTOR pathway through AMPK inhibition as previously reported. 30 The Raf/MEK/ERK and PI3K/AKT signaling pathways cooperatively link with each other to enhance the proliferation and apoptotic resistance capacity in cancer cells. 31 Both signaling pathways are activated by growth factor receptors. These 2 pathways can exert complementary and redundant functions when only a single pathway is inhibited. 32 Our results showed that Compound C or Compound C+ AMF, inhibited the phosphorylation of Akt in T98 and U251 cells (Figure S3) . The AMF did not significantly enhance Akt/mTOR signaling inhibition.
In contrast, the ERK signaling pathway is known to play a major role in cell proliferation, and the effect of Compound C on the phosphorylation of ERK is not fully understood. In the current study, we found that Compound C promoted the phosphorylation of ERK in a dose-dependent manner in T98 cells. To our showed that the AMF decreased the Compound C-induced phosphorylation of ERK and increased the BAX/Bcl2 ratio and cleaved caspase-3 expression (n = 4; ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001). D, The cytotoxic effect of U0126 was analyzed using the XTT assay. T98 cells were pretreated with U0126 (10 μmol/L) for 1 h and then treated with 5 μmol/L Compound C for 24 h (n = 4; ns, not significant; **P < 0.01, ***P < 0.001). E, Representative images of the western blot analysis showed that U0126 dephosphorylated ERK and increased cleaved caspase-3 expression in T98 cells in the presence/absence of 5 μmol/L Compound C for 24 h knowledge, this is the first study to report that Compound C increased the phosphorylation of ERK ( Figure 4A ). Interestingly, Compound C did not increase but rather decreased ERK signaling in NHA ( Figure S2 ).
Because the AMF enhanced the apoptotic effect in the presence of Compound C, we examined the protein expression of BCL-2 and BAX. These proteins are known to be key regulators of apoptosis represented by anti-apoptotic proteins. 33, 34 They regulate the efflux of pro-apoptotic molecules from mitochondria and other organelles.
Compound C also increased the protein expression of BAX/Bcl2 and caspase-3 in T98 cells in a dose-dependent manner ( Figure 4A ). Taken 
| An alternating magnetic field inhibited compound C-induced autophagy, resulting in increasing cytotoxicity of compound C in T98 cells
Autophagy is a catabolic process whereby cells self-digest intracellular organelles. 34 Autophagy is an evolutionarily conserved and genetically controlled process, resulting in the selection of cellular proteins and organelles for degradation by the lysosomes. Vucicevic et al A randomized, double-blind, placebo-controlled trial using chloroquine, an autophagy inhibitor, was performed for glioblastoma multiforme. 35 This study concluded that adding chloroquine to Compound C-induced apoptosis in glioma and breast carcinoma. Compound C also inhibited cell proliferation in glioma and human pancreatic cancer cell lines. 8, 29 We examined whether an AMF | 3491 resulting in increased levels of cleaved caspase-3 ( Figure 6D,E) . Interestingly, the AMF also increased the cytotoxicity of TMZ and BCNU induced-cytotoxicity in U251 glioma cells ( Figure S6 ).
| DISCUSSION
In It is known that autophagy is activated by chemotherapy or radiation. 36, 37 Therefore, autophagy is attracting attention as a target of cancer treatment. Our study indicated that an AMF increased the cytotoxicity of Compound C through the suppression of autophagy.
An AMF has a potential therapeutic antitumor effect in the presence of Compound C, whereas the underlying mechanism remains unknown. It is well known that the mitochondria play an important role in energy transduction. Mitochondrial iron and the other transition metals that are magnetic bodies are used by cytochrome c oxidase (CcO), the final enzyme complex in the electron transport chain.
Therefore, the AMF may affect the metal in the mitochondria and induce instability of the mitochondrial electron transport system. The mechanism connecting the effect of the AMF and anti-cancer drugs, including Compound C, needs to be determined in future studies.
Other issues also remain before clinical application will be possible. First, the different conditions (kHz or Arms) of the electric device need to be further investigated. However, it is difficult to change the experimental conditions because our device is an indus- 
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